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Abstract
Sepsis is one of the leading causes of morbidity and mortality in hospitalized patients worldwide. Molecular technologies for
rapid detection of microorganisms in patients with sepsis have only recently become available. LightCycler SeptiFast test M
grade
(Roche Diagnostics GmbH) is a multiplex PCR analysis able to detect DNA of the 25 most frequent pathogens in bloodstream
infections. The time and labor saved while avoiding excessive laboratory manipulation is the rationale for selecting the
automated MagNA Pure compact nucleic acid isolation kit-I (Roche Applied Science, GmbH) as an alternative to conventional
SeptiFast extraction. For the purposes of this study, we evaluate extraction in order to demonstrate the feasibility of automation.
Finally, a prospective observational study was done using 106 clinical samples obtained from 76 patients in our ICU. Both
extraction methods were used in parallel to test the samples. When molecular detection test results using both manual and
automated extraction were compared with the data from blood cultures obtained at the same time, the results show that
SeptiFast with the alternative MagNA Pure compact extraction not only shortens the complete workflow to 3.57 hrs., but also
increases sensitivity of the molecular assay for detecting infection as defined by positive blood culture confirmation.
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Introduction
Sepsis is a clinical condition that is defined by objective signs
establishing systemic inflammatory response syndrome (SIRS)
together with the physician’s suspicion of infection. Frequently,
clinicians have to initiate early therapy with broad-spectrum
empiric antibiotics before support is available from microbiological
data that would confirm and focus their decisions [1]. Of the
different strategies for treating the septic condition that ranges
from systemic inflammatory response syndrome (SIRS) to septic
shock and multiorganic failure, appropriate antibiotic therapy and
prompt initial treatment have the greatest impact on reducing
mortality and morbidity associated with sepsis [2,3,4]. In fact,
there have been reports of an excessive in-hospital mortality of
31.4% in patients initially treated inadequately and who developed
nosocomial infection in the ICU [5].
Recent publications [6,7,8] on the utility of molecular methods
stress the potential advantages, in terms of aiding adequate
therapy choice, of having a system that is able to rapidly diagnose
and confirm an infection associated with SIRS. LightCycler
SeptiFast test M
grade (Roche Diagnostics GmbH) is a multiplex
real-time PCR based assay which is able, in about six hours, to
detect the presence of DNA from 25 important bacterial and
fungal species relevant for sepsis and nosocomial infection. The
microorganisms covered by the test are the cause of approximately
90% of all blood stream infections and the range of species tested
by SeptiFast includes those most frequently treated inadequately,
as well as those producing the most difficult to treat infections
[9,10]. Like most diagnostic molecular tests, this method has a
workflow designed in three phases: extraction, amplification/
detection (real-time PCR) and data analysis. The nucleic acid
isolation in SeptiFast test protocol includes successive steps of
mechanical/enzymatic lysis and glass fiber filtration and is a
mostly hands-on procedure for extraction that takes 3.52 hrs. The
aim of the present study was to compare the efficacy of
conventional extraction following SeptiFast manufacturer’s rec-
ommendations against MagNA pure compact nucleic acid
isolation kit I (cat. 03 730 964 001) (Roche Applied Science,
Penzberg, GmbH), a rapid automatic DNA extraction method
(approximately 34 min.) based on magnetic nanoparticles.
Our data show that automated MagNA pure compact
extraction followed by SeptiFast detection not only shortens the
complete workflow of the test from 6.54 hrs. to 3.57 hrs., but also
increases assay sensitivity of the molecular assay for detecting
infection defined by positive blood culture confirmation.
Methods
Extraction reagents controls
We used two types of DNA as controls for testing the extraction
methods analyzed. Firstly, we used genomic Deoxyribonucleic
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D4889 (USA)) as bacterial DNA standard for testing extraction.
This DNA has been purified by equilibrium buoyant density
gradient ultracentrifugation in cesium chloride, the solution was
adjusted to a concentration of 5.30 A260 units of DNA per ml and
lyophilized. Approximate average size is 16 kb and ratio A268/
A280 is 1.9. Escherichia coli DNA is one of the targets included in
SeptiFast test Master list.
And secondly, to evaluate the functionality of both methods we
also used 20 reference microbial strains obtained from the
American Type Culture Collection (ATCC) (USA): Acinetobacter
baumannii (ATCC 19686), Enterobacter cloacae (ATCC 13847), Serratia
marcenscens (ATCC 14756), Stenotrophomonas maltophilia (ATCC
51331), Escherichia coli (ATCC 25922) Klebsiella pneumoniae (ATCC
70063), Proteus mirabilis (ATCC 12453), Pseudomonas aeruginosa
(ATCC 27853), Staphylococcus aureus (ATCC 25923), Staphylococcus
epidermidis (ATCC 12228), Streptococcus pneumoniae (ATCC 49619)
Streptococcus agalactiae (ATCC 13813) Enterococcus faecalis (ATCC
29212) Enterococcus faecium (ATCC 35667), Candida albicans (ATCC
90028) Candida tropicalis (ATCC 750) Candida parapsilosis (ATCC
22019), Candida glabrata (ATCC 1526), Candida krusei (ATCC 6258),
Aspergillus fumigatus (ATCC 36607). The microbial sample mixture
was composed of 10
4 CFU/ml. of each strain in donor whole
blood and genomic DNA from those strains was analyzed after
extraction.
Quality control
Two types of experiments were conducted to validate and
control quality of extraction procedures performed:
(a) Fluorometric determination of DNA recovery as a measure
of extraction yield. For DNA quantification we used the Quant-
iT
TM Assay Kit (Invitrogen, USA) with the QubitH fluorometer
following manufacturer instructions. The kit includes concentrated
assay reagent, dilution buffer, and pre-diluted DNA standards.
The assay is accurate for initial sample concentrations between
50 pg/mL and 200 ng/mL. Common contaminants, such as salts,
free nucleotides, solvents, detergents, or protein are well tolerated
in the assay.
In our study, serial dilutions (1:2) of the E. coli DNA standard
resuspended in TE buffer was extracted with the two extraction
methods tested; recovery with MagNA pure compact was done
using Total NA plasma 100–400 protocol that produces a final
elution volume of 100 ml. Conventional SeptiFast manual
extraction produces a final elution volume of 300 ml. Both
extraction procedures were done and detection of strains in the
mixture were performed by using SeptiFastH identification
software, following manufacturer instructions.
(b). Testing of the performance of microbial SeptiFastH
detection ability after extraction of reference strains using both
methods. 20 reference strains obtained from American Culture
Collection were mixed with a concentration of 10
4 CFP/ml for
each strain. Using equal amounts of each microorganism in donor
whole blood. Genomic DNA from those strains was analyzed after
extraction using both procedures here described. Melting
temperature (Tm) and peak height for each strain was calculated
after using SeptiFastH amplification, also adequacy of the values
obtained was ascertained following the manufacturer criteria for
assigning genera and species identification.
Patient inclusion criteria and selection
A total of 72 patients from our Intensive Care and Anesthe-
siology Services, between May 2007 and May 2008, were included
in the present study; all met criteria for SIRS and suspected sepsis
on admission. Our study received hospital institutional review
board approval (Comite de Investigacion, Complejo Universitario
de Santiago) and patients’ written informed consent was obtained
before initiation at the intensive care unit. The final mortality rate
of the group was 32.8%. Based on clinicians’ suspicion of sepsis,
106 whole blood samples were obtained, consisting of one sample
for SeptiFast and two bottles (aerobic and anaerobic) for blood
culture (BacT-Alert (Biomerieux) France). When considered
appropriate, additional blood culture series and other microbiol-
ogy cultures from distinct compartments were taken for standard
infection follow up. On the same days, biochemical and
immunological techniques were performed to analyze additional
clinical parameters. Clinical scores were done in all cases studied.
The resulting clinical profile of the study group is shown in Table 1.
Blood cultures and phenotypic Identification
Whole blood (10 ml) was collected for culture by either venous
or arterial draw and inoculated in two resin containing blood
culture bottles (FN/FA BacT-Alert, Biomerieux, France). Bottles
were loaded into a BacT-Alert 3D automated blood culture
instrument (Biomerieux, France). Once flagged by the instrument
for detectable growth, fluid was withdrawn for gram stain and
appropriate agar-based culture plates. Isolated colonies were
analyzed either by an automated identification system (Vitek II
Table 1. Clinical Observational study summary.
Patients num. 72
Samples num 106
Age 64 (21–92)
gender
male 53
female 19
Mortality% 37,5
Basal Disease
respiratory 18
cardiovascular 18
alcoholism 10
oncologic 6
digestive 6
psychiatric 4
neurologic 2
various causes 6
other cause 2
APACHE II
0–4 0
5–9 2
10–14 9
15–19 15
20–24 12
25–29 15
30–34 11
.34 8
Patients from our Intensive Care and Anesthesiology departments were
sequentially selected between May 2007 and May 2008 to be included in the
study, and had to meet criteria for SIRS and suspected sepsis on admission.
Previous antibiotic treatment was not a criterion for rejection.
doi:10.1371/journal.pone.0013387.t001
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identification tests.
Conventional microbiology
All other phenotypic or serological analysis processed to isolate
microbial pathogens coming from body compartments other than
blood are included under this heading. After gram and isolation in
appropriate agar-based culture plates, selected colonies were
analyzed and identified as above.
SeptiFastH multiplex analysis
The LightCycler SeptiFast test M
grade is an in vitro nucleic
amplification test for detection and identification of bacterial and
fungal DNA from microorganism specified on the SeptiFast
Master List and found in human K-EDTA blood using the
LightCycler 2.0 Instrument (Roche Diagnostics GmbH). The test
is used in conjunction with clinical presentation, established
microbiological assays, and other laboratory markers to confirm
bacterial/fungal blood stream infections.
The LightCycler SeptiFast test M
grade extraction is based on
mechanical lysis of the 1,5 ml of whole blood specimens
performed by using the SeptiFast Lysis kit and the Magna Lyser
instrument (Roche Diagnostics GmbH). 1 ml. of lysed blood
samples are incubated at elevated temperature with protease and
chaotropic lysis buffer and, then, internal controls are added.
Afterward, the mixture is transferred into a spin column with a
glass fiber filter insert. The human genomic DNA and the
microbial target DNA binds to the surface of the glass fiber, which
is an unspecific absorption process. Unbound substances are
removed in two consecutive washing steps. Then, the nucleic acid
that is bound is eluted at elevated temperature and the eluates are
subjected to PCR analysis. In our cases a dilution 1:3 of the sample
obtained is used for the next step. The real time PCR
amplification of target DNA is done in three parallel reactions
(gram positive bacteria, gram negative bacteria and fungi) and
detection by specific Hybprobe probes is performed using the
LightCycler 2.0 instrument (Roche Diagnostics GmbH) with
uracil-N-glycosylase enzyme to prevent the risk of amplicon
contamination. The emitted fluorescence is measured in one of the
instrument’s four different channels. After completion of amplifi-
cation, a melting curve analysis is done and a report is generated
by dedicated identification software (SeptiFast identification
software). A detailed description of the test methodology has been
described elsewhere [6].
Alternative SeptiFastH protocol using MagNa pure
extraction system
As with the conventional protocol, we start with mechanical lysis
by using 1.5 ml of blood in one Septifast Lysis kit tube (cat. Num.:04
404 432 001) and shaking at 7000 rpm for 70 sc. on MagNA Lyser
instrument (Roche Diagnostics GmbH). We use MagNA pure
Compact Nucleic Acid Isolation Kit (cat. Num.: 03 730 964 001)
according to manufacturer instructions. The protocol used for
automated extraction is the Bacterial DNA protocol for the MagNA
pure Compact instrument and we add 400 ml of blood lysed sample
plus 4 ml of internal control for SeptiFast. The final elution volume is
200 ml. We follow manufacturer directions for the following
SeptiFast amplification and detection steps.
Negative controls included in test do not work with MagNA
pure instrument, so we use instead 400 ml of tissue-lysis buffer
(4 M urea, 200 mM Tris, 20 mM NaCl,200 mM EDTA, pH 7.4)
from high pure PCR template preparation kit (Roche Applied
Science, cat. Num.:11-796-828-001, USA) plus 4 ml of internal
control for SeptiFastH as an alternative for the negative control
included in the commercial kit, which eventually may help to rule
out possible contamination concerns. (For further information see
‘‘Data S1’’)
Statistical analysis
The following linear model has been used to estimate yield:
‘‘DNA recovered’’=‘‘yield’’6‘‘initial DNA quantity’’+‘‘error’’. Where
‘‘error’’ is assumed to be normally distributed with a mean of zero
and a variance specified for each method. The estimated yield for
each method is shown in the legend for Figure 1. Sensitivity,
specificity and kappa analysis were performed using categorical
variables in two-by-two tables (Data S2). Interpretation of strength
of agreement for kappa was based on Landis R.J. and Koch G.G.
criteria [11]. Analysis was performed by using R project for
statistical computing.
Results
1. Yield and DNA size of eluted samples after extraction
using SeptifastH with manual extraction vs. SeptiFast
with MagNA pure compact extraction
We used E. coli standard DNA (Sigma-Aldrich (USA)) to test the
comparative DNA recovery ability of the two extraction methods
(SeptiFast with manual extraction vs. SeptiFast with MagNA pure
compact extraction using protocol ‘‘Total NA Plasma 100–400’’).
The rationale for using this bacterial DNA standard is that the
nucleic acid contained represents one of the microorganism
included in SeptiFast master list. In fact, has additional functional
and experimental advantages: it can be tested with the molecular
SeptiFast detection system and renders positive.
To analyze extraction yield, we used the concentration of DNA
recovered in the eluate after serial dilution to compare the ability
of MagNA pure compact magnetic nanoparticles and the
conventional technique with respect to unspecific absorption of
nucleic acids. Up to the absorption limit of nanoparticles, we
found the absorption capacity of both surfaces in terms of yields to
be similar (24.14% for MagNA pure versus 28.54% for SeptiFast
conventional extraction). Variability as well as and the total
amount of blood processed (1000 ml vs. 400 ml) and the real
volumes of final eluates (300 ml vs. 200 ml) were all higher using
manual SeptiFastH extraction method. Data is shown in Figure 1.
2. Master list Strain performance on SeptiFastH detection
with manual and automatic extraction
SeptiFast software employing a specific range of Temperature
Melting (Tm) and peak height values was used to determine
microbial species included on the master list and test the ability of
both methods to recover microbial DNAs. After testing a mixture
of 20 microbial strains (see Table 2), no discrepancies were found
in the species reported by the instrument using both manual and
automated SeptiFast methods.
3. Diagnostic values of SeptiFast detection with manual
and automatic extraction in clinical samples
We tested 106 samples obtained from 72 ICU patients using
both SeptiFast with the manual extraction protocol and SeptiFast
with an alternative automatic extraction using MagNA pure
compact. Results are shown in Tables 3 and 4.
Firstly, the sensitivity and specificity measures of SeptiFast with
automated extraction were compared to those for SeptiFast with
manual extraction, which was used as a reference for positive
infection. Then, successive comparisons of both SeptiFast
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for positive infection. Concordance was accepted when results
were identical insofar as defining the species of the pathogen
detected.
Discussion
Sepsis is an inflammatory state resulting from the systemic
response to bacterial infection. Conventional blood cultures are
used for routine etiological diagnosis of confirmed bacteremia in
septic patients. These tests are based on the viability of the
microorganisms invading the blood compartment and laboratory
reporting takes more than 24 hrs [12]. In the clinical setting, the
need to start therapy with empiric broad spectrum antibiotics
immediately after establishing clinical suspicion of sepsis frequently
compromises our ability to isolate viable microorganisms in blood.
Moreover, the size of the blood compartment and the amount of
viable bacteria may also affect detection of disease in SIRS
patients with suspected sepsis. Thus, clinicians are often forced to
make critical empirical antibiotic decisions without the aid of
microbiologically confirmed data [13].
In the present study we evaluate a fast molecular alternative for
diagnosing pathogenic microorganisms directly from blood
samples. Although molecular detection of microbial DNA in
Figure 1. Comparative ability of the two extraction methods (SeptiFastH with manual extraction and SeptiFastH with MagNA pure
compact extraction using protocol ‘‘Total NA Plasma 100–400’’) using Escherichia coli DNA standard (Sigma Aldrich). SeptiFastH with
manual extraction obtains more total amount of DNA than SeptiFastH with MagNA pure compact extraction. Points represent value of the media and
also minor and maximum values for each dilution are represented. Boxplots represents the yields obtained using the two alternative methods,
calculated as concentrations not as total product obtained in the eluate. (Wilcoxon rank sum test is W=51, p-value=3.89e-05).
doi:10.1371/journal.pone.0013387.g001
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both methods are valid for defining infection and can be useful in
current medical practice for improving our ability to follow up
septic patients [14]. Conventional blood cultures detect viable
microorganisms and make it possible to perform resistance analysis
in vivo. On the other hand, molecular testing is not affected by
antibiotic usage or any other viability issue and allows us to detect
the presence of microbial DNA under conditions that would be
adverse for conventional culturing methods.
Molecular diagnosis procedures involve three consecutive steps:
nucleic acid extraction, amplification (PCR) and, detection and
data analysis (target identification, normally carried out with
dedicated software). In recent years a number of automated
nucleic acid extraction methods have become available for use in
conjunction with PCR techniques. These technologies are
designed to be faster and more labor efficient. These automated
methods reduce human error, improve precision, obtain repro-
ducible results and allow analysis of large number of samples [15].
The aim of the present study was to evaluate an automatic
method suitable for use with SeptiFast and ascertain if automating
the protocol maintains detection sensitivity and specificity. In
addition to the advantages mentioned above, this method would
avoid possible interferences from manipulation in different
laboratories. We evaluated two aspects, first extraction which
was determined in terms of yields and second functionality, which
is the ability to identify targets included on the test master list.
SeptiFast (Roche Diagnostics GmbH) is a multiplex PCR on
real time analysis for simultaneous detection of 25 bacterial and
fungal DNAs in whole blood and has been authorized for clinical
diagnostic use in Europe. It requires up to 6. 5460.27 hrs. [8] for
reporting, furthermore, SeptiFast test currently uses a manual
extraction procedure based on mechanical/enzymatic lysis and
glass fiber filtration that involves extensive time (up to 211. 4 min)
and labor, There are currently a number of choices for automating
this process [16,17].
We have selected MagNA pure compact automated system for
SeptiFast extraction because it provides a number of advantages.
Firstly, MagNA pure magnetic nanoparticles are one of the fastest
extraction methods commercially available [18] and extraction
takes only 34 min. (15 min of labor depending on the number of
samples processed). Secondly, the total capacity of MagNA pure
compact (8 samples per run) is well suited to use with SeptiFast.
This alternative to the standard method produces a total testing
time of 3.58 hrs, including mechanical lysis (42 min) and detection
(139 min).
Using E. coli DNA standard, our findings indicate that this
automated absorption process yields similar amounts of DNA as
the conventional manual method (24.14% for MagNA pure versus
28.54% for SeptiFast conventional extraction) up to the point
where the binding surface of MagNA pure nanoparticles (which is
smaller than the binding surface for glass fibers) becomes
saturated. Due to the presence of leukocytes, the amount of
DNA in blood samples for septic patients is often above this
saturation value and, thus, the final total amount of DNA
extracted with the manual method is approximately three times
the amount of DNA eluted with MagNA pure extraction [19].
To determine the automated test’s level of functionality, we
validated the correct identification of different microbial strains
included on the SeptiFastH target master list. After SeptiFast
analysis of the 20-microbial-target sample mix, we compared
Table 2. Tm and peak height values obtained for 20 different pathogens included in SeptiFastH test master list.
Assay Microorganism ATCC num. Tm MP Peak TM SFM Peak SeptiFastH MP SeptiFastH SFM
Gram negatives A. baumannii 19686 65,38 0,42 64,00 0,08 ++
E. cloacae 13847 66,39 0,78 66,23 0,30 ++
S. marcescens 14756 58,00 0,36 58,00 0,24 ++
S. maltophilia 51331 63,09 0,16 63,08 0,38 ++
E. coli 25922 51,00 0,64 51,00 0,60 ++
K. pneumoniae 70063 59,22 0,12 59,01 0,19 ++
P. mirabilis 12453 55,01 0,25 54,63 0,32 ++
P. aeruginosa 27853 58,00 0,94 58,00 1,03 ++
Gram positives S.aureus 25923 61,81 0,12 61,42 0,09 ++
S.epidermidis 12228 51,60 0,08 51,43 0,11 ++
S.pneumoniae 49619 56,80 0,23 56,69 0,46 ++
S.agalactiae 13813 51,13 0,07 51,80 0,01 ++
E.faecalis 29212 62,78 0,03 62,29 0,02 ++
E.faecium 35667 54,61 0,06 54,60 0,05 ++
Funghi C.albicans 90028 55,92 1,90 55,77 1,82 ++
C.tropicalis 750 59,00 0,09 59,00 0,06 ++
C. parapsilosis 22019 54,97 0,06 54,00 0,03 ++
C. glabrata 1526 59,70 0,40 59,99 0,34 ++
C. Krusei 6258 51,77 0,27 51,66 0,55 ++
A. fumigatus 36607 56,68 0,42 58,51 1,61 ++
After SeptiFast analysis of the 20-microbial-target sample mix, we compared melting temperature (Tm) and peak heights for both extraction methods, SeptiFastH with
MagNA pure compact extraction (MP), and SeptiFastH with manual extraction (SFM). In order to be considered valid, values had to be within accepted ranges of the
SeptiFast identification software (SIS). Melting temperature (Tm) and peak heights are presented along with SIS interpretation of values obtained.
doi:10.1371/journal.pone.0013387.t002
Automated Multiplex for Sepsis
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13387melting temperature (Tm) and peak heights for both extraction
methods. In order to be considered valid, values had to be within
accepted ranges of the SeptiFast identification software. As Table 2
indicates, Tm and peak data for standard ATCC microbial targets
included in the master list presented acceptable values and fell
within approved ranges. The rationale that SeptiFast uses for
establishing these semiqualitative ranges is based on studies of
bacterial DNA in blood samples from healthy subjects and has
been adjusted for carriage contamination and reservoir of bacterial
DNA in human blood [20].
In sum, the results show that MagNA pure extraction followed
by LightCycler SeptiFast detection was valid under the standard
conditions tested and constitutes a plausible alternative to
conventional manual extraction. Moreover, it provides consider-
ably savings in terms of labor time (49 min.) and extraction time
(34 min.).
To test the clinical utility of SeptiFast with MagNA pure
extraction, an observational prospective study of 72 patients was
carried out. A total of 106 clinical samples were obtained involving
parallel SeptiFast testing with both extraction methods as well as
simultaneous blood cultures (2 bottles: one in aerobic and the
other in anaerobic conditions). Concordance of both extraction
methods was statistically analyzed by comparing validity measures
with binary diagnostic tests (sensitivity and specificity), likelihood
ratios, and positive and negative predictive value. These measures
quantify a test’s ability to distinguish individuals with and without
a certain disease. In our case, an objective definition of disease is
difficult [21], but for the purposes of comparison we have based
our criteria for confirming infection in the blood compartment
either on the results of the SeptiFast manual test or blood culture.
As can be seen in Table 3, when using positive SeptiFast with
manual extraction values as criteria for infection, SeptiFast with
Table 3. Results obtained testing samples in parallel.
Case Num.
(Ref.)
MagNapure/SeptiFast
result
Manual/SeptiFast
result
BloodCulture/Vitek II
result
Observations: other bacteriological
cultures
1.- (169) CoNS CoNS CoNs
2.- (185) E. coli Neg Neg
3.- (194d2) E. faecalis Neg E. faecalis Ascitic fluid (+) Ent. faecalis
4.- (195) S. pneumoniae Neg Neg Sputum (+) S.pneumoniae
5.- (204d2) E.faecium E. faecium E. faecium Ascitic fluid (+) E. faecium
6.- (210) S. pneumoniae Neg S. pneumoniae
7.- (211d1) S. pneumoniae Neg S. pneumoniae
8.- (220) CoNS CoNS CoNS Catheter culture (+) CoNS
9.- (JAE) Neg Neg B. fragilis Ascitic fluid (+) B. fragilis
10.(235d3) CoNS Neg CoNS
11.(236d1) E.coli E. coli E.coli
12.(236d2) E.coli E.coli E.coli
13.(242d2) K. pneumoniae/oxytoca K.pneumoniae/oxytoca K. pneumoniae
14.(242d3) K. pneumoniae/oxytoca K.pneumoniae/oxytoca K. pneumoniae
15.(244d1) S. aureus S. aureus S. bovis
16.(251d3) CoNS Neg CoNS
17.-(255) S. pneumoniae Neg S. peumoniae Bronquial aspirate(+) S. pneumoniae
18.-(263) C. albicans S. aureus C. albicans Catheter, surgical wound (+) C. albicans
19.-(265) Neg K. pneumoniae Neg
20.(265d2) CoNS CoNS CoNS
21.(271d1) S. aureus S. aureus S.aureus Synovial fluid, Bronquial aspirate (+) S. aureus
22.(271d2) St. aureus S. aureus S. aureus Bronquial aspirate (+) S. aureus
23.-(272) St. aureus Neg S aureus
24.(280d1) Neg Neg E. faecalis/MRSA
25.-(311) S. marcencens S. marcencens S. marcencens Catheter tip (+) S. marcencens.
26.-(313) S. marcencens. S. marcencens S. marcencens
27.-(327) C. parapsilosis C. parasilopsis/P. aeruginosaC parapsilosis Urine (+) C. parapsilosis/Bronquial aspirate(+)P .
aeruginosa
28.-(329) S. aureus S.aureus S.aureus
29.-(343) E. cloacae/E. coli E. coli E. cloacae Bronquial aspirate/wound exhudate (+) E. cloacae
30.- (355) P. aeruginosa Neg P aeruginosa Bronquial aspirate (+) P. aeruginosa
Additional 76 samples were Negative by all three methods
Data obtained after testing 106 samples by three alternative methods, Negative (Neg) results and discrepancies are in bold. (Abbreviators: Bacteroides fragilis (B. fragilis)
and Streptococcus bovis (S. bovis) Coagulase negative Staphylococci (CoNS) and Meticillin-resistant Staphylococcus aureus (MRSA) are bacteria not previously cited in
the manuscript.)
doi:10.1371/journal.pone.0013387.t003
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cies between manual and automatic procedures may be due to
differences in the amount of blood used that lead to differences in
enzymatic effectiveness during the lysis step. In addition, the
presence of genomic DNA or other DNA content may affect the
unspecific absorption of microbial DNA detected by SeptiFast
[22]. Similar sensitivity (56%) is also found when the conventional
SeptiFast test is compared with positive simultaneous blood
cultures. Besides the potential interference on unspecific absorp-
tion, discrepancies may also derive from the effect of previous
antibiotic treatment as well as the isolation of viable microorgan-
isms not included on test master list. Surprisingly, when we
compared simultaneous positive blood cultures and SeptiFast with
automatic extraction, we found a sensitivity of 92%. In fact, kappa
values indicated an almost perfect agreement between the species
defined after identification of isolates obtained in blood cultures
and SeptiFast with MagNA pure compact extraction.
For the 27 positive and 79 negative cases identified by SeptiFast
with MagNA pure compact extraction, specificity and positive and
negative predictive values were consistently high compared to
conventional SeptiFast or blood culture results. It is in positive
values, where the rare discrepancies appeared. In fact, SeptiFast
with MagNA pure extraction closely resembles blood cultures, but
presents discrepancies with the manual extraction test. In our
study, the six discrepancies between SeptiFast with automatic
extraction and blood cultures involved the growth of one bacteria
by blood cultures not covered on the SeptiFast list (Bacteroides
fragilis). Another case was a Streptococcus bovis, which could be
explained by the fact that one procedure uses phenotypic criteria
for species assignment (Vitek II) while the other uses genotypic
criteria (Internal transcribed spacer (ITS) region sequence
homology). Two other bacteria were isolated from blood cultures
but were negative for SeptiFastH (one Staphylococcus aureus meticilin-
resistant and one Enterococcus faecalis), these cases and two other
bacteria detected by SeptiFastH with automatic extraction but with
negative cultures (Escherichia coli and Streptococcus pneumoniae) were
detected in patients who received empiric antibiotic therapy
previous to their inclusion in the study. Regarding manual and
automatic SeptiFastH protocols, discrepancies basically involved
negative results for conventional extraction and positive results for
extraction with MagNA pure, except in one case, where Klebsiella
pneumoniae was detected with the manual method while sample was
negative for automatic extraction and blood culture.
Occasional discrepancies between multiplex real time PCR and
positive simultaneous blood cultures have previously been reported
[23,24,25] and should be reasonably expected in five situations: 1)
when patients are previously treated with antibiotics that partially
cover the bacteria, yielding positive molecular results and negative
cultures, 2) when microorganisms are not included on the test
master list, 3) when there is a mixed infection of microorganisms
detected in the same LightCycler 2.0 channel, due to the
competitive characteristics of the amplification procedure (limited
availability of dNTPs), 4) when different criteria for assigning
species identification is used in phenotypic identification (mainly
biochemical properties) and molecular diagnosis (genetic homol-
ogies) and, finally, 5) in very few cases we had observed that
certain species with similar Tms may be misinterpreted by the
identification software of the molecular method (p.e., Klebsiella
oxytoca and Enterobacter cloacae). All these discrepancies may be
meaningful for individual cases, but only rarely occur when
molecular diagnostic tests are used routinely. In any case, due to
these possibilities it is always advisable to rely on a combination of
clinical data, conventional cultures and molecular tests for the best
patient follow up.
Another issue to consider is the need for precise clinical
indications regarding when to use the test [26,27,28]. It is clear
Table 4. Differential diagnostic value of manual and automatic procedure.
A
LightCyclerH Septifast MagNA PureH
compact extraction vs. LightCyclerH
Septifast manual extraction
LightCyclerH Septifast
manual extraction vs. Blood
culture+VitekII identification
LightCyclerH Septifast MagNA PureH
compact extraction vs. Blood
culture+Vitek II identification.
Sensitivity 88.88 (65–98) 51.85 (31–71) 88.88 (70–97)
Specificity 87.5 (78–93) 98.73 (93–99) 96.2 (87–98)
Positive predictive value 59.25 (38–72) 93.33 (68–99) 88.88 (70–98)
Negative predictive value 97.46 (91–99) 85.71 (76–92) 96.2 (89–99)
Prevalence 16.98 25.47 25.47
Likelihood ratio Positive test 7,11 (3.99–12.65) 40.96 (5.64–297.03) 23.38 (7.64–71.53)
Likelihood ratio Negative test 0.126 (0.034–0.47) 0.487 (0.329–0.72) 0.115 (0.039–0.33)
B
Proportion of agreement
(strength of agreement)
0.87 (moderate) 0.86 (moderate) 0.94 (almost perfect)
Bias Index 0.08 20.11 0
Prevalence Index 20.57 20.6 20.49
Kappa (8) 0.637 0.592 0.85
C
volume tested 400ml/1000ml 1000 ml/20ml. 400 ml./20 ml.
Note: (95% Confidence interval calculated with binomial expansion).
(See Supplemental data). A.: comparison of identification values obtained after using Accuracy matrix for both SeptiFast methods and blood culture+identification
using Vitek II system. (Test Characteristics: Sensitivity: how good the test is at detecting an microorganism, Specificity: how good the test is at identifying patients with
negative values, Positive predictive value: how often a patient with a positive test in fact has the microorganism, Negative predictive value: how often a patient with a
negative test in fact does not have the microorganism.) B: Agreement matrix using kappa, which corrects the proportion of agreement due to chance and C: volumes of
sample used in different experiments as reference for the compartment analyzed.
doi:10.1371/journal.pone.0013387.t004
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diagnostic approaches [29]. The utility of the test depends on the
patient’s clinical status because the blood sample must adequately
reflect the compartment that is going to be analyzed. Nevertheless,
transient bacteremia, biofilms, and pathologies with low bacterial
levels can affect the test’s detection ability (i.e endocarditis or
neutropenic patients) [30]. Despite some limitations that require
professional judgment, the use of molecular diagnostic techniques
constitutes an overall improvement in terms of providing well-
grounded support for clinical therapeutic decisions.
In conclusion, our study has shown that SeptiFast test with
MagNA pure compact extraction reduces workflow from 6.
54 hrs. to 3.56 hrs. when compared to SeptiFast with the
conventional manual extraction. The use of this alternative
automated protocol does not affect sensitivity or specificity of the
method and actually increases assay sensitivity for detecting
infection defined by positive blood culture confirmation. In our
experience, combined use of rapid molecular testing and
conventional microbiology represents an advantage for the septic
patient and improves clinical decisions for achieving adequate
treatment.
Supporting Information
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